VE416

End Allergies Together Announces Winners of $1 Million Grand Challenge to...

News Wire ~ 3rd Party Press Release - 2020/02/12

New microbiome treatments and targets win Challenge as decided by distinguished panel of scientists, investors and entrepreneurs.

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food...

News Wire ~ 3rd Party Press Release - 2019/07/02

First clinical study of a bacterial consortium for treating food allergy will initially be studied in patients with history of peanut allergy.

Company Developing Microbiome-Derived Food Allergy Therapy Raises $27 Million

Dave Bloom - 2018/12/28

Product candidate being developed may safely induce permanent tolerance to food allergens.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

Tag: VE416

End Allergies Together Announces Winners of $1 Million Grand Challenge to...

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food...

Company Developing Microbiome-Derived Food Allergy Therapy Raises $27 Million